vTv Therapeutics (VTVT)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	41.57 mm	41.57 mm	41.57 mm	41.57 mm	41.57 mm	41.57 mm
Cash burn (monthly)	1.32 mm	(no burn)	2.17 mm	2.02 mm	2.14 mm	1.95 mm
Cash used (since last report)	6.67 mm	n/a	10.98 mm	10.25 mm	10.83 mm	9.87 mm
Cash remaining	34.90 mm	n/a	30.59 mm	31.32 mm	30.74 mm	31.70 mm
Runway (months of cash)	26.5	n/a	14.1	15.5	14.4	16.3

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

VTVT institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	21	18	+16.7%
Opened positions	7	12	-41.7%
Closed positions	4	1	+300.0%
Increased positions	3	0	NEW
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	7.60 bn	3.22 bn	+135.7%
Total shares	18.14 mm	17.82 mm	+1.8%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
G42 Investments AI Holdings RSC	10.39 mm	$5.73 mm	0.0%
Medpace Investors	5.40 mm	$6.53 mm	0.0%
MacAndrews & Forbes	1.54 mm	$13.05 mm	0.0%
Samsara BioCapital	265.62 k	$2.26 mm	0.0%
Samsara BioCapital	206.78 k	$2.86 bn	NEW
FMR	178.20 k	$2.43 bn	0.0%
Baker Bros. Advisors	97.31 k	$1.34 bn	NEW
Vanguard	41.56 k	$566.02 mm	0.0%
Geode Capital Management	11.63 k	$158.49 mm	+12.9%
UBS UBS	7.51 k	$103.73 mm	+767.4%

Largest transactions	Shares	Bought/sold	Change
Samsara BioCapital	206.78 k	+206.78 k	NEW
Baker Bros. Advisors	97.31 k	+97.31 k	NEW
UBS UBS	7.51 k	+6.65 k	+767.4%
JPM JPMorgan Chase & Co.	1.80 k	+1.80 k	NEW
Geode Capital Management	11.63 k	+1.33 k	+12.9%
MS Morgan Stanley	1.15 k	+1.15 k	NEW
Planning Capital Management	0.00	-625.00	EXIT
RY Royal Bank of Canada	383.00	+383.00	NEW
Tower Research Capital	0.00	-269.00	EXIT
Strengthening Families & Communities	0.00	-173.00	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

VTVT insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
18 Nov 24	Sekhri Paul J	Class A Common Stock	Buy	Acquire P	No	Yes	16.9569	1,844	31.27 k	5,000
15 Nov 24	Sekhri Paul J	Class A Common Stock	Buy	Acquire P	No	Yes	16.8781	1,778	30.01 k	3,156
15 Nov 24	Sekhri Paul J	Class A Common Stock	Buy	Acquire P	No	Yes	16.3528	1,378	22.53 k	1,378
25 Jun 24	Fahed Al-Marzooqi	Director stock option Class A Common Stock	Grant	Acquire A	No	No	17.22	3,000	51.66 k	9,555
25 Jun 24	Spiegelman Daniel K	Director stock option Class A Common Stock	Grant	Acquire A	No	No	17.22	6,000	103.32 k	6,000
25 Jun 24	Phillips Anne M.	Director stock option Class A Common Stock	Grant	Acquire A	No	No	17.22	860	14.81 k	6,860
25 Jun 24	Phillips Anne M.	Director stock option Class A Common Stock	Grant	Acquire A	No	No	17.22	2,250	38.74 k	6,000
25 Jun 24	Baker Bros. Advisors	Non- Qualified Stock Option Common Stock	Grant	Acquire A	Yes	No	17.22	983	16.93 k	983
25 Jun 24	Baker Bros. Advisors	Non- Qualified Stock Option Common Stock	Grant	Acquire A	Yes	No	17.22	983	16.93 k	983
25 Jun 24	Baker Bros. Advisors	Non- Qualified Stock Option Common Stock	Grant	Acquire A	Yes	No	17.22	6,000	103.32 k	6,000

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

11 Feb 25

Alliance Global Partners Initiates Coverage On vTv Therapeutics with Buy Rating, Announces Price Target of $35

9 Dec 24

Alliance Global Partners analyst James Molloy initiates coverage on vTv Therapeutics (NASDAQ:VTVT) with a Buy rating and announces Price Target of $35.

Press releases

From Benzinga Pro

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

9 Dec 24

WESTON, Fla., Dec. 9, 2024 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions,

vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference

2 Dec 24

HIGH POINT, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical stage biopharmaceutical company with a portfolio of novel small molecules and a lead program in diabetes, today